Bill No. 1416 aims to establish guidelines for group insurance plans covering state employees in Oklahoma regarding the inclusion of non-opioid treatments in their preferred drug lists (PDLs). The bill defines key terms such as "group insurance plan," "health care prescriber," "insurer," and "non-opioid treatment." It mandates that insurers must ensure that non-opioid drugs approved by the United States Food and Drug Administration (FDA) for pain management are not disadvantaged compared to opioid medications on the PDL. However, the bill allows for the preference of one opioid over another or one non-opioid over another.

The legislation also clarifies that these provisions apply to non-opioid treatments that have been reviewed and approved for coverage by the relevant group insurance plans or insurers, including those provided under contracts with pharmacy benefits managers. The bill is set to take effect on November 1, 2025.